Paclitaxel for Triple-Negative Breast Cancer: 56 Real Stories

Stage IV HR-Positive Breast Cancer: Alison's Survivor Story

Patient Info: Alison, Female, Under 40 | Stage IV

Biomarkers: ER-positive; PR-positive; HER2-positive

Metastatic Site: Cervical/neck lymph nodes

Alison reported complete remission since August 2017 while continuing intermittent maintenance chemotherapy, most recently 1 month of treatment followed by 2 months off.

The Patient StoryRead more →

Stage III HR-Positive Invasive Ductal Carcinoma: Stefanie's Survivor Story

Patient Info: Stefanie, Female | Stage III

Biomarkers: ER-positive, PR-positive and HER2-positive

Stefanie completed chemotherapy, breast-conserving surgery, prolonged Herceptin and 30 radiation treatments, then moved into survivorship while still adjusting to the lasting effects of treatment.

The Patient StoryRead more →

Stage II Triple-Negative Breast Cancer: Lucy's Survivor Story

Patient Info: Lucy, Female, Under 40 | Stage II

Biomarkers: Germline BRCA1 mutation; triple-negative breast cancer

Surgical pathology was all clear on June 17 after a strong chemotherapy response. Lucy described herself as cancer-free and continued oncology reviews every 3–4 months while planning delayed reconstruction.

The Patient StoryRead more →

Stage II Triple-Negative Breast Cancer: Melissa's Survivor Story

Patient Info: Melissa, Female | Stage II

Biomarkers: Triple-negative breast cancer; BRCA testing negative; NBN gene mutation identified on later testing

Melissa completed pregnancy-adapted cancer treatment, later underwent risk-reducing surgery and reconstruction, and was raising both daughters.

The Patient StoryRead more →

Stage IIA triple-negative neuroendocrine breast carcinoma with chemoimmunotherapy response

Patient Info: Anonymized, Female, 70+ | Stage II

Biomarkers: Triple-negative neuroendocrine breast carcinoma with PD-L1 CPS >=10, and reported germline BRCA1/2 mutation.

As of March 2025, 12 months after surgery, follow-up imaging and tumor-marker testing showed no local recurrence or distant metastasis, and she remained in good general condition.

PubMed CentralRead more →

Stage IV Triple-Negative Breast Cancer: Erin's Patient Story

Patient Info: Erin, Female | Stage IV

Biomarkers: ER-negative; PR-negative; HER2-negative; later tumor responded to androgen signaling

Metastatic Site: Lung; brain

As of June 2026, Erin was living with metastatic triple-negative breast cancer involving lung and brain, with tumors shrinking on ongoing Gemzar plus carboplatin chemotherapy every 2 weeks.

The Patient StoryRead more →

Stage III Triple-Negative Breast Cancer: Stephanie's Survivor Story

Patient Info: Stephanie, Female | Stage III

Biomarkers: ER-negative; PR-negative; HER2-negative; BRCA1 mutation

As of June 2026, Stephanie described being a 10-year survivor after Stage III BRCA1-positive triple-negative breast cancer, with remission shown after chemotherapy and no recurrence described.

The Patient StoryRead more →

Metastatic triple-negative breast cancer with orbital and bone metastases responding to nab-paclitaxel plus everolimus

Patient Info: Anonymized, Female, 70+ | Stage IV

Biomarkers: Primary breast cancer was ER-low, PR/HER2 negative. Orbital metastasis was triple-negative with AKT1 exon 4 mutation.

Metastatic Site: right orbit/orbital mass; bone

At 6-month follow-up, systemic disease was stable, ocular symptoms had significantly improved, orbital metastases were stable on MRI, and the response was described as RECIST partial response/progression-free interval while treatment continued.

PubMed CentralRead more →

Stage IIB triple-negative metaplastic breast cancer with early metastatic recurrence: durable response to pembrolizumab-based therapy

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: Triple-negative metaplastic breast cancer with PD-L1 CPS 83.2, BRCA1/2 negative

Metastatic Site: lung, sternum

As of May 2026, she had more than 30 months of disease control after pembrolizumab-based therapy for early recurrent metastatic metaplastic breast cancer, with only mild residual sternal uptake and no disease progression.

PubMed CentralRead more →

Triple-Negative Breast Cancer: Jacqueline's Patient Story

Patient Info: Jacqueline Bennett, Female, Under 40

Biomarkers: Initial ER-negative, PR-negative, HER2-negative; later HER2-positive

Jacqueline completed treatment for initial Stage IA triple-negative breast cancer during pregnancy and later developed a HER2-positive, hormone receptor-negative breast cancer. After 3 of 6 current treatments, the tumor was no longer visible on ultrasound or MRI, with targeted therapy and double mastectomy still planned.

The Patient StoryRead more →

Triple-negative breast cancer diagnosed during pregnancy: remission

Patient Info: Anonymized, Female, Under 40

Biomarkers: ER-negative; PR-negative; HER2-negative

The patient remains in remission 30 months after surgery. Immune-related brachial plexopathy after treatment improved after steroids, IVIG, and plasmapheresis, with electrophysiologic resolution and near-complete strength and sensory recovery.

PubMed CentralRead more →

Non-metastatic metaplastic triple-negative breast cancer with residual disease after chemotherapy

Patient Info: Anonymized, Female, 40s

Biomarkers: Metaplastic triple-negative breast cancer; HER2 0

The patient had an initial partial response to neoadjuvant chemotherapy but then progressed before surgery. Modified radical mastectomy found substantial residual metaplastic carcinoma with 0/21 nodes involved, followed by adjuvant radiotherapy and metronomic capecitabine.

PubMed CentralRead more →

Stage IIIB triple-negative metaplastic breast cancer: urgent mastectomy and reconstruction after rapid progression on neoadjuvant therapy

Patient Info: Anonymized, Female, 40s | Stage III

Biomarkers: ER-negative; PR-negative; HER2-negative; nuclear grade 3

At 18-month follow-up, she was disease-free after urgent mastectomy, axillary dissection, flap/skin-graft reconstruction, resumed chemotherapy, and radiation for rapidly progressive triple-negative metaplastic breast cancer.

PubMed CentralRead more →

Metastatic triple-negative breast cancer with sacituzumab-govitecan pneumonitis and progression

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: ER-negative; PR-negative; HER2-negative

Metastatic Site: lung

Sacituzumab-govitecan pneumonitis improved with corticosteroids and half-dose rechallenge did not reproduce pneumonitis, but follow-up CT showed one new pulmonary metastasis and enlargement of previous lung metastases; PFS on sacituzumab govitecan was 5.37 months.

PubMed CentralRead more →

Stage 3 triple-negative breast cancer complicated by immunotherapy endocrine toxicity

Patient Info: Anonymized, Female, 40s | Stage III

Biomarkers: ER-negative; PgR-negative/PR-negative; HER2 0; Ki-67 70%; triple-negative breast cancer

After neoadjuvant therapy complicated by immune-related hypothyroidism, adrenal insufficiency, and suspected hypophysitis, surgery showed residual ypT1c ypN0 triple-negative disease. Pembrolizumab was stopped, adjuvant capecitabine was completed in June 2025, and endocrine replacement/follow-up continued.

PubMed CentralRead more →

Stage I AR-positive triple-negative invasive apocrine breast carcinoma: disease-free after surgery, radiotherapy and chemotherapy

Patient Info: Anonymized, Female, 50s | Stage I

Biomarkers: Triple-negative apocrine breast carcinoma with androgen receptor 90%

At 1-year follow-up, she remained disease-free with no clinical or radiologic evidence of recurrence.

PubMed CentralRead more →

Triple-negative breast cancer with pathologic complete response after neoadjuvant chemoimmunotherapy complicated by immune toxicity

Patient Info: Anonymized, Female, 40s | Stage III

Biomarkers: ER-negative; PR-negative; HER2-negative

Left mastectomy on November 17 confirmed pathologic complete response, and 5-month follow-up showed no residual hepatic, dermatological, metabolic, or neurological sequelae from the treatment-related complications.

PubMed CentralRead more →

Triple-negative breast cancer history with later chest wall sarcomatoid carcinoma treated by embolization, ablation, and chemotherapy

Patient Info: Anonymized, Female, 40s

Biomarkers: Initial breast cancer was triple-negative. Later chest-wall lesion was weak ER-positive, PR/HER2-negative

By February 2025, the treated chest wall lesion had decreased to about 13 x 7 mm after embolization, radiofrequency ablation, and albumin-bound paclitaxel plus cisplatin, with no peripheral or distant metastatic foci seen.

PubMed CentralRead more →

Triple-negative node-positive breast cancer with complete pathologic response and benign nodal nevi

Patient Info: Anonymized, Female, 50s

Biomarkers: Triple-negative breast cancer; BRCA testing negative. Axillary melanocytic cells looked benign.

Pathology showed complete response in the breast, no residual breast carcinoma in the sampled specimen, and axillary nodal melanocytic proliferations interpreted as benign nodal nevi rather than metastatic melanoma or breast carcinoma.

PubMed CentralRead more →

Synchronous triple-negative breast cancer and rectal adenocarcinoma complicated by hepatitis B reactivation

Patient Info: Anonymized, Female, 50s

Biomarkers: Triple-negative breast cancer with pathogenic BRCA1 mutation; hepatitis B reactivation occurred during treatment.

At 3-year follow-up, she remained healthy and disease-free after treatment for synchronous triple-negative breast cancer and mid-rectal adenocarcinoma, with hepatitis B reactivation controlled on entecavir.

PubMed CentralRead more →

Stage III Triple-Negative Breast Cancer: Lynn's Survivor Story

Patient Info: Lynn Leiro, Female, Under 40 | Stage III

Biomarkers: ER-negative; PR-negative; HER2-negative

Lynn achieved complete response after breast cancer treatment and remission from therapy-related acute lymphocytic leukemia after CAR T cell therapy and bone marrow transplant; as of July 2025, nearly 1 year post-transplant, she was doing better and getting stronger.

City of HopeRead more →

Stage IIIB triple-negative breast cancer: complete response after LVAD-supported neoadjuvant immunotherapy

Patient Info: Anonymized, Female, 60s | Stage III

Biomarkers: ER-negative; PR-negative; HER2-negative; Ki-67 95%; nuclear grade 3, triple negative

As of July 2025, breast cancer remained in remission 2.5 years after mastectomy, after neoadjuvant paclitaxel/carboplatin/pembrolizumab, surgery, radiation, and 1 year of adjuvant pembrolizumab.

PubMed CentralRead more →

Triple-negative sebaceous carcinoma of the breast: no recurrence after multimodality treatment

Patient Info: Anonymized, Female, Under 40

Biomarkers: Triple-negative sebaceous breast carcinoma; EMA-positive; Ki-67 50-60%; inherited breast/ovarian cancer testing negative for pathogenic variants.

As of May 2025, after surgery, adjuvant chemotherapy, and radiation, she had 5 years of follow-up with no evidence of neoplastic recurrence.

PubMed CentralRead more →

Stage III HR-Positive Breast Cancer: Christine's Survivor Story

Patient Info: Christine, Female, Under 40 | Stage III

Biomarkers: ER-positive; PR-positive; HER2-positive

Three years after diagnosis, Christine described herself in the survivorship stage and focused on the physical and emotional effects that continued after active treatment.

The Patient StoryRead more →